Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 182Breast 27Tumor-Agnostic 4Other 4Lymphoid 4Plasma cell 3Other hematologic neoplasm 3Myeloid 3Head & Neck 3Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Leuprolide × Tumor-Agnostic × Clear all
NCT01442246 2024-09-19

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

UNICANCER

Phase 3 Active not recruiting
700 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00380406 2017-04-05

PROOF

Ottawa Hospital Research Institute

Phase 3 Completed
30 enrolled
Tumor-Agnostic

Neoplasms

NCT00586898 2016-03-25

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
36 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT01011751 2015-07-30

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Takeda

Phase 3 Completed
311 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡